Psoriasis: how controlling starches and sugars can affect symptoms and metabolic risks

Initial note

Article previously published and now updated based on recent scientific research and editorial guidelines. The text is for informational and educational purposes: it does not replace individual medical evaluation. For clinical decisions, always consult your doctor or specialist.

In brief

• Psoriasis is a chronic inflammatory skin disease with frequent metabolic associations (obesity, metabolic syndrome, diabetes).
• The glycemic load of meals rich in sugars and starches can promote systemic inflammation through mechanisms related to glucose, insulin, and inflammatory mediators.
• Reductions in body weight and low glycemic index/load diets have been associated with clinical improvements in some studies, especially in overweight or obese patients.
• Steroid medications can increase glycemia; phototherapy (UV) remains an effective therapy but should be used with appropriate clinical criteria.
• Evidence primarily comes from observational studies and trials on subgroups; individual recommendations must be shared with a doctor.

Abstract: what does science say?

Psoriasis is a chronic inflammatory condition with frequent metabolic comorbidities. Epidemiological studies indicate an association between psoriasis and a higher risk of metabolic syndrome and type 2 diabetes; the magnitude of the risk varies with age, disease severity, and the presence of obesity. Plausible biological mechanisms include insulin resistance, alterations in lipid profile, production of pro-inflammatory cytokines, and interactions between adipose tissue, the immune system, and the gut microbiota. Nutritional interventions aimed at reducing the glycemic load of meals, along with weight loss in overweight individuals, have shown favorable effects on systemic markers of inflammation and, in some trials, an improvement in the clinical severity of psoriasis. However, most available evidence comes from observational studies or trials with limitations (small size, short follow-up). For this reason, the observed relationships should be interpreted with caution and contextualized within the individual therapeutic pathway.

What it means in practice

For those living with psoriasis, evidence suggests that controlling the glycemic load of meals and, when necessary, weight loss, can be useful tools as part of a multidisciplinary approach. The association between psoriasis and the risk of diabetes and metabolic syndrome is documented in large reviews and cohort studies: these works show an average increase in risk compared to the general population. [1] [2] [3] These results indicate an epidemiological link between skin disease and metabolic alterations, not a simple direct causal relationship. In patients with psoriasis, it is therefore reasonable to assess metabolic status (weight, waist circumference, glucose, blood pressure, lipid profile) as part of clinical follow-up. [7]

Nutrition and glycemic load

Glycemic load (GL) measures how much a meal increases glycemia: meals rich in refined starches and sugars have high GL and insulin responses. Controlled dietary studies show that low-GL diets can reduce systemic markers of inflammation, such as high-sensitivity C-reactive protein (hs-CRP), especially in overweight or obese individuals. [5] This reduction in systemic inflammation represents a plausible biological pathway through which diet can influence skin disease, although the direct link meal → worsening of psoriasis requires further evidence.

Sun exposure, phototherapy, and caution

Controlled UV exposure is an established therapy for many patients with psoriasis and acts by modifying the cutaneous immune profile and inducing apoptosis of infiltrating lymphocytes. [9] However, the effect of the sun on lesions that are in an activation phase can be different: the Koebner phenomenon (appearance of new lesions after trauma or irritation) is a recognized clinical reality and suggests caution in the presence of intense disease activity. Medical phototherapy should therefore be performed under specialist supervision.

Key points to remember

Brief operational framework and practical points, without clinical prescriptions:

• Psoriasis is associated with a higher prevalence of obesity, metabolic syndrome, and risk of diabetes: metabolic surveillance is part of integrated management. [2] [3]
• Reducing the glycemic load of a meal (minimizing simple sugars and preferring whole grains and fiber-rich carbohydrates) can lower systemic inflammatory markers in some contexts. [5]
• In overweight patients, weight loss has been correlated with clinical improvements in psoriasis in controlled trials; this is particularly true for structured energy reduction interventions. [6] [7]
• Systemic and, in part, injectable corticosteroid medications can increase glycemia: consider the metabolic impact in the risk-benefit balance. [8]
• Phototherapy is effective but requires clinical indication and control: avoid unprescribed exposures during phases of skin reactivation. [9]

Limitations of the evidence

It is crucial to distinguish between epidemiological correlation and proof of causation. Many of the relationships between psoriasis and metabolic alterations emerge from observational studies (cohorts, case-control studies, database analyses), which document statistical associations but do not automatically prove that one condition causes the other. [1] [2] Experimental studies and randomized trials evaluating dietary or weight loss interventions often include selected populations (e.g., obese patients) and have limited sample sizes or short follow-up, which reduces the ability to generalize the results. [6] The proposed biological mechanisms (insulin resistance, cytokine-mediated microinflammation, interaction with adipose tissue and microbiota) are plausible and supported by experimental data, but their translation into universally valid clinical recommendations requires further long-term trials with adequate control of confounding factors. [4] Furthermore, pharmacological interventions (e.g., glucocorticoids) have known metabolic effects and should be considered as potential mediating or amplifying factors of the glycemic alterations observed in patients with psoriasis. [8]

Editorial conclusion

Current knowledge supports the idea that psoriasis management goes beyond treating skin lesions alone: an integrated approach that includes evaluating the metabolic profile and, when appropriate, interventions on diet and body weight, can improve clinical outcomes and overall health status. Evidence on reducing glycemic load and clinical benefits is encouraging, especially in overweight or obese individuals, but is not yet definitive for extension to the entire population with psoriasis. The decision to modify diet, start a weight loss program, or undergo phototherapy should be made in a team with the attending physician, dermatologist, and nutritionist. The goal remains to integrate effective therapies, monitor metabolic risks, and respect patient preferences and safety.

Editorial note

This article was published in a previous version and has now been updated according to scientific and responsible dissemination criteria: peer-reviewed revisions, randomized trials, and international guidelines have been consulted to ensure transparency and accuracy. The content is informative and does not replace personalized medical advice. For specific questions, refer to your attending physician.

SCIENTIFIC RESEARCH

1. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84-91. https://doi.org/10.1001/2013.jamadermatol.406
2. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654-662. https://doi.org/10.1016/j.jaad.2012.08.015
3. Li W, Han J, Hu FB, Curhan GC, Qureshi AA. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol. 2012;132(2):291-298. https://doi.org/10.1038/jid.2011.319
4. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with disease severity. J Rheumatol. (study on insulin resistance and PsA). https://doi.org/10.3899/jrheum.140021
5. Neuhouser ML, Schwarz Y, Wang C, Breymeyer K, Coronado G, Wang CY, Noar K, Song X, Lampe JW. A low-glycemic load diet reduces serum C-reactive protein and modestly increases adiponectin in overweight and obese adults. J Nutr. 2012;142(2):369-374. https://doi.org/10.3945/jn.111.149807
6. Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149(7):795-801. https://doi.org/10.1001/jamadermatol.2013.722
7. Ko, Chi & Yeh (Cochrane Review). Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019; CD011972. https://doi.org/10.1002/14651858.CD011972.pub2
8. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15(5):469-474. https://doi.org/10.4158/EP08331.RAR
9. Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg. 2013;17(1):6-12. https://doi.org/10.2310/7750.2012.11124

[If some complete references are not available in the local archive, the corresponding placeholder is indicated: [DOI to be verified]]